Structure Therapeutics (GPCR) Set to Release Quarterly Earnings on Thursday

Structure Therapeutics (NASDAQ:GPCR) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Structure Therapeutics to announce earnings of ($0.3250) per share and revenue of $50.00 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, analysts expect Structure Therapeutics to post ($1.87) EPS for the current fiscal year and ($2.09) EPS for the next fiscal year.

Structure Therapeutics Trading Down 0.3%

NASDAQ GPCR opened at $21.48 on Thursday. The company has a market cap of $1.50 billion, a PE ratio of -21.48 and a beta of -1.30. Structure Therapeutics has a 12 month low of $20.50 and a 12 month high of $94.90. The stock has a 50 day moving average of $34.65 and a 200-day moving average of $49.91.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on GPCR shares. HC Wainwright restated a “buy” rating on shares of Structure Therapeutics in a report on Wednesday, September 9th. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Citizens Jmp reiterated a “market outperform” rating and issued a $110.00 price target on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Weiss Ratings cut shares of Structure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 23rd. Finally, Wall Street Zen downgraded shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $110.91.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic diseases. The company uses structure-based drug discovery and focuses on G protein-coupled receptors (GPCRs), a broad class of drug targets involved in metabolic and cardiovascular processes.

Its lead product candidate is GSBR-1290, an investigational oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. Structure Therapeutics is also advancing additional discovery and preclinical programs intended to address metabolic and related chronic diseases.